ATHX - Athersys, Inc.
| Previous Close | 1.6100 |
| Open | 1.6100 |
| Bid | 1.5500 x 4000 |
| Ask | 1.7500 x 4000 |
| Day's Range | 1.5800 - 1.6650 |
| 52 Week Range | 1.3500 - 2.3700 |
| Volume | 426,577 |
| Avg. Volume | 707,630 |
| Market Cap | 248.628M |
| Beta (3Y Monthly) | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1940 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.67 |
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of ATHX earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Athersys Inc Earnings Call
- GlobeNewswire•12 days ago
Athersys to Present at Jefferies 2019 Healthcare Conference
Athersys, Inc. (ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City. Dr. Van Bokkelen’s presentation will take place at 11 AM Eastern Time on June 7, 2019 and will focus on the Company’s mission and the clinical development of its MultiStem® cell therapy. The talk will also summarize the recent positive data from its exploratory Phase 1/2 clinical study evaluating MultiStem cell therapy for the treatment acute respiratory distress syndrome (ARDS), and the ARDS clinical program has received Fast Track designation from the U.S. Food and Drug Administration for the next phase of development.
- GlobeNewswire•19 days ago
Athersys to Participate in four Events at the International Society of Cell and Gene Therapy Conference
CLEVELAND, May 28, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year’s International Society for Cell and Gene Therapy.
- Simply Wall St.•23 days ago
Volatility 101: Should Athersys (NASDAQ:ATHX) Shares Have Dropped 25%?
While it may not be enough for some shareholders, we think it is good to see the Athersys, Inc. (NASDAQ:ATHX) share...
- GlobeNewswire•27 days ago
Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference
Athersys, Inc. (ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the longest running, large-scale conference in the world offering groundbreaking research in pulmonary, critical care and sleep medicine.
- Benzinga•29 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...
- Motley Fool•last month
Here's Why Athersys Rose as Much as 15.2% Today
The FDA has given the company's lead drug platform a potential leg up in development.
Motley Fool•last monthAthersys (ATHX) Q1 2019 Earnings Call Transcript
ATHX earnings call for the period ending March 31, 2019.
- GlobeNewswire•last month
Athersys Reports First Quarter 2019 Results
CLEVELAND, May 08, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2019. Highlights of the first quarter of.
- ACCESSWIRE•last month
Athersys, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time. ...
- Motley Fool•2 months ago
Here's Why Athersys Is Soaring Today
The stem cell pioneer announced an update with its most important collaborator.
- Zacks•2 months ago
Athersys (ATHX) Upgraded to Strong Buy: Here's What You Should Know
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- GlobeNewswire•2 months ago
HEALIOS K.K. Announces Enrollment of First Patient in Japan in the ONE-BRIDGE Study of MultiStem® Treatment for Acute Respiratory Distress Syndrome
Athersys, Inc. (ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem® cell therapy treatment of patients who suffer from acute respiratory distress syndrome (“ARDS”). The clinical trial investigates the efficacy and safety of MultiStem therapy for patients with pneumonia-induced ARDS.
- GlobeNewswire•2 months ago
Athersys to Host Investor Day in New York City
Athersys, Inc. (ATHX) announced today that the company will host an investor day on Tuesday, May 14, 2019. The investor day will include presentations from the Company’s management team as well as experts in the fields of stroke and ARDS. Dr. David Chiu, MD, FAHA, Medical Director at the Eddy Scurlock Stroke Center at Houston Methodist Hospital will be discussing the MASTERS-2 clinical trial for stroke.
- GlobeNewswire•2 months ago
Athersys to Host First Quarter Financial Results Call
CLEVELAND, April 10, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, May 8,.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ATHX earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 Athersys Inc Earnings Call
- Zacks•3 months ago
What Makes Athersys (ATHX) a New Buy Stock
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Motley Fool•3 months agoAthersys Inc (ATHX) Q4 2018 Earnings Conference Call Transcript
ATHX earnings call for the period ending December 31, 2019.
- GlobeNewswire•3 months ago
Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
Substantial progress over the year, advancing programs andexpanding collaboration with HEALIOS K.K. Management to host conference call at 4:30 PM EST today CLEVELAND, March.
- Zacks•3 months ago
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
- Simply Wall St.•4 months ago
Is Athersys, Inc.’s (NASDAQ:ATHX) CEO Paid Enough Relative To Peers?
Gil Van Bokkelen has been the CEO of Athersys, Inc. (NASDAQ:ATHX) since 1995. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look atRead More...
- GlobeNewswire•4 months ago
Athersys to Host Year-End 2018 Financial Results Call
CLEVELAND, Feb. 14, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019,.
- Zacks•5 months ago
Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
